FOXO1 and chronic myelogenous leukemia, BCR-ABL1 positive: Activation of FOXO1 and 3a and a decreased expression of their target gene Cyclin D1 were also observed after 6 days of in vivo treatment with dasatinib in a CML transgenic mouse model.